✓ Translated by DotMD AI Clinical Council Source: Journal of affective disorders • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #25554994 ↗

Randomized Controlled Trial: Impairment and distress patterns distinguishing the melancholic depression subtype: an iSPOT-D report (N = 339)

Original Paper Title: “Impairment and distress patterns distinguishing the melancholic depression subtype: an iSPOT-D report”

Elena Rostova (AI Quant) Rigor Score
87 / 100
Sample Size (Participants)
N = 339
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Findings provide new insights into a melancholic profile of reduced ability to function interpersonally or effectively deal with one׳s emotions. This distinctly poorer capacity for social skills remained post-treatment. The pre-treatment profile may account for some of the difficulty in achieving remission or response with treatment.
  • Study Design & Sample: Randomized Controlled Trial published in Journal of affective disorders (N = 339 human participants).
  • Biostatistical Rigor Score: 87/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Journal of affective disorders (2015), this randomized controlled trial evaluating 339 human participants investigated: This study seeks to provide a comprehensive and systematic evaluation of baseline clinical and psychological features and treatment response characteristics that differentiate Major Depressive Disorder (MDD) outpatients with and without melancholic features. Key clinical takeaway: Findings provide new insights into a melancholic profile of reduced ability to function interpersonally or effectively deal with one׳s emotions. This distinctly poorer capacity for social skills remained post-treatment. The pre-treatment profile may account for...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Journal of affective disorders, 2015-03-15; N = 339; Rigor 87/100): Findings provide new insights into a melancholic profile of reduced ability to function interpersonally or effectively deal with one׳s emotions. This distinctly poorer capacity for social skills remained post-treatment. The pre-treatment profile may account for some of the difficulty in achieving remission or response with treatment.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: citalopram-hydrobromide → Rx: citalopram → Rx: sertraline-hcl → Rx: sertraline-hydrochloride → Condition: depression → Condition: bipolar-disorder-current-episode-depressed-moderate → Condition: bipolar-disorder-current-episode-mixed →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 25554994: Randomized Controlled Trial: Impairment and distress patterns distinguishing the melancholic depression subtype: an iSPOT-D report (N = 339)

3 of 3 Free Questions Remaining